About us Contacts Drug interactions: 390 212
Drug search by name

Eptifibatide and Ticlopidine

Determining the interaction of Eptifibatide and Ticlopidine and the possibility of their joint administration.

Check result:
Eptifibatide <> Ticlopidine
Relevance: 26.07.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Ask your doctor before using eptifibatide together with ticlopidine. This can cause you to bleed more easily. You may need a dose adjustment in addition to special testing of your blood. Call your doctor promptly if you have any unusual bleeding or bruising, vomiting, blood in your urine or stools, headache, dizziness, or weakness. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR CLOSELY: The combination of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors and other drugs that inhibit platelet aggregation may significantly increase the risk of bleeding, especially from arterial puncture sites. The mechanism is synergistic pharmacologic effects. However, in a phase 3 clinical trial (TRITON-TIMI 38) evaluating the safety and efficacy of prasugrel and clopidogrel in patients with acute coronary syndrome (ACS) undergoing percutaneous intervention (PCI), the use of a GP IIb/IIIa inhibitor (type used not uniformly captured in the study) did not increase the relative risk of bleeding with prasugrel as compared with clopidogrel when the thienopyridine loading dose was administered shortly before or at the time of PCI.

MANAGEMENT: Extraordinary precautions are recommended if these drugs must be used together, including monitoring platelet counts and hemoglobin concentrations. In addition, invasive procedures, such as urinary catheterization, nasogastric or nasotracheal intubation, and even venous punctures should be avoided or minimized. Non-compressible venous access sites, such as jugular or subclavian sites, should be avoided.

References
  • Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S "Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A." Clin Pharmacol Ther 67 (2000): 305-13
  • "Product Information. ReoPro (abciximab)." Lilly, Eli and Company, Indianapolis, IN.
  • "Product Information. Integrilin (eptifibatide)." Schering Laboratories, Kenilworth, NJ.
  • O'Donoghue M, Antman EM, Braunwald E, et al. "The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla" J Am Coll Cardiol 54 (2009): 678-85
Eptifibatide

Generic Name: eptifibatide

Brand name: Integrilin

Synonyms: n.a.

Ticlopidine

Generic Name: ticlopidine

Brand name: Ticlid

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction